We are analyzing https://link.springer.com/article/10.1007/s00262-003-0445-0.

Title:
Role of IL-13 in regulation of anti-tumor immunity and tumor growth | Cancer Immunology, Immunotherapy
Description:
Major mediators of anti-tumor immunity are CD4+ T h 1 cells and CD8+ cytotoxic T lymphocytes (CTLs). In tumor-bearing animals, the T h 1- and CTL-mediated anti-tumor immunity is down-regulated in multiple ways. Better understanding of negative regulatory pathways of tumor immunity is crucial for the development of anti-tumor vaccines and immunotherapies. Since immune deviation toward T h 2 suppresses T h 1 development, it has been thought that induction affecting a T h 2 immune response is one of the mechanisms that down-regulate effective tumor immune responses. Recent studies using T h 2-deficient signal transducer and activator (Stat6) KO mice demonstrated that this hypothesis was the case. IL-13 is one of the T h 2 cytokines that has very similar features to IL-4 through sharing some receptor components and Stat6 signal transduction. It has been thought that IL-13 is not as critical for immune deviation as IL-4 since it cannot directly act on T cells. However, recent studies of IL-13 reveal that this cytokine plays a critical role in many aspects of immune regulation. Studies from our lab and others indicate that IL-13 is central to a novel immunoregulatory pathway in which NKT cells suppress tumor immunosurveillance. Here we will describe biological properties and functions of IL-13, its role in the negative regulation of anti-tumor immunity, and effects of IL-13 on tumor cells themselves.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

google, scholar, pubmed, cas, interleukin, cells, immunol, receptor, human, article, tumor, immunity, cancer, alpha, cell, donaldson, exp, med, zurawski, terabe, berzofsky, immune, mice, role, regulation, antitumor, cytokine, usa, puri, chain, kawakami, growth, cytotoxic, immunosurveillance, access, characterization, mckenzie, hodgkin, gene, privacy, cookies, content, research, park, lymphocytes, regulatory, responses, nkt, functions, proc,

Topics {✒️}

month download article/chapter fibroblast-derived inflammatory agents ctl-mediated anti-tumor immunity nkt cell-mediated repression related subjects t-cell-stimulating activities t-cell-derived cytokine il-4r-stat6 pathway lymphocyte-mediated tumor immunity article cancer immunology il-4-mediated irs-1 phosphorylation negative regulatory pathways jong myun park & jay cell-stimulatory factor 1 il-13 receptor-targeted cytotoxin il-4 receptor alpha-chains c-reactive protein production helminth-induced inflammation cd1d-restricted nkt cells ige responses induced immune deviation tumour immunosurveillance full article pdf expresses b-cell de waal malefyt article forms part privacy choices/manage cookies squamous cell carcinoma dendritic cell maturation key regulatory cytokine nuclear factor-kappa 2 immune response vaccine research section interleukin-13 receptor expression b-cell function check access instant access stat6-deficient mice anti-tumor immunity tumor-bearing animals interleukin 4-deficient mice ko mice demonstrated spontaneous rejection nzb/nzw mice anti-tumor vaccines tumor cells engineered de vries je murine b16 melanoma insulin receptor motif enhanced tumor immunity

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Role of IL-13 in regulation of anti-tumor immunity and tumor growth
         description:Major mediators of anti-tumor immunity are CD4+ T h 1 cells and CD8+ cytotoxic T lymphocytes (CTLs). In tumor-bearing animals, the T h 1- and CTL-mediated anti-tumor immunity is down-regulated in multiple ways. Better understanding of negative regulatory pathways of tumor immunity is crucial for the development of anti-tumor vaccines and immunotherapies. Since immune deviation toward T h 2 suppresses T h 1 development, it has been thought that induction affecting a T h 2 immune response is one of the mechanisms that down-regulate effective tumor immune responses. Recent studies using T h 2-deficient signal transducer and activator (Stat6) KO mice demonstrated that this hypothesis was the case. IL-13 is one of the T h 2 cytokines that has very similar features to IL-4 through sharing some receptor components and Stat6 signal transduction. It has been thought that IL-13 is not as critical for immune deviation as IL-4 since it cannot directly act on T cells. However, recent studies of IL-13 reveal that this cytokine plays a critical role in many aspects of immune regulation. Studies from our lab and others indicate that IL-13 is central to a novel immunoregulatory pathway in which NKT cells suppress tumor immunosurveillance. Here we will describe biological properties and functions of IL-13, its role in the negative regulation of anti-tumor immunity, and effects of IL-13 on tumor cells themselves.
         datePublished:2003-11-11T00:00:00Z
         dateModified:2003-11-11T00:00:00Z
         pageStart:79
         pageEnd:85
         sameAs:https://doi.org/10.1007/s00262-003-0445-0
         keywords:
            Cerebral Malaria
            Tumor Rejection
            Immune Deviation
            Tumor Immunosurveillance
            Negative Regulatory Pathway
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0445-0/MediaObjects/s00262-003-0445-0fhb1.tif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0445-0/MediaObjects/s00262-003-0445-0fhb2.tif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:53
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Masaki Terabe
               affiliation:
                     name:National Institutes of Health
                     address:
                        name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Jong Myun Park
               affiliation:
                     name:National Institutes of Health
                     address:
                        name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jay A. Berzofsky
               affiliation:
                     name:National Institutes of Health
                     address:
                        name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Role of IL-13 in regulation of anti-tumor immunity and tumor growth
      description:Major mediators of anti-tumor immunity are CD4+ T h 1 cells and CD8+ cytotoxic T lymphocytes (CTLs). In tumor-bearing animals, the T h 1- and CTL-mediated anti-tumor immunity is down-regulated in multiple ways. Better understanding of negative regulatory pathways of tumor immunity is crucial for the development of anti-tumor vaccines and immunotherapies. Since immune deviation toward T h 2 suppresses T h 1 development, it has been thought that induction affecting a T h 2 immune response is one of the mechanisms that down-regulate effective tumor immune responses. Recent studies using T h 2-deficient signal transducer and activator (Stat6) KO mice demonstrated that this hypothesis was the case. IL-13 is one of the T h 2 cytokines that has very similar features to IL-4 through sharing some receptor components and Stat6 signal transduction. It has been thought that IL-13 is not as critical for immune deviation as IL-4 since it cannot directly act on T cells. However, recent studies of IL-13 reveal that this cytokine plays a critical role in many aspects of immune regulation. Studies from our lab and others indicate that IL-13 is central to a novel immunoregulatory pathway in which NKT cells suppress tumor immunosurveillance. Here we will describe biological properties and functions of IL-13, its role in the negative regulation of anti-tumor immunity, and effects of IL-13 on tumor cells themselves.
      datePublished:2003-11-11T00:00:00Z
      dateModified:2003-11-11T00:00:00Z
      pageStart:79
      pageEnd:85
      sameAs:https://doi.org/10.1007/s00262-003-0445-0
      keywords:
         Cerebral Malaria
         Tumor Rejection
         Immune Deviation
         Tumor Immunosurveillance
         Negative Regulatory Pathway
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0445-0/MediaObjects/s00262-003-0445-0fhb1.tif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0445-0/MediaObjects/s00262-003-0445-0fhb2.tif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:53
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Masaki Terabe
            affiliation:
                  name:National Institutes of Health
                  address:
                     name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Jong Myun Park
            affiliation:
                  name:National Institutes of Health
                  address:
                     name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jay A. Berzofsky
            affiliation:
                  name:National Institutes of Health
                  address:
                     name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:53
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Institutes of Health
      address:
         name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
         type:PostalAddress
      name:National Institutes of Health
      address:
         name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
         type:PostalAddress
      name:National Institutes of Health
      address:
         name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Masaki Terabe
      affiliation:
            name:National Institutes of Health
            address:
               name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Jong Myun Park
      affiliation:
            name:National Institutes of Health
            address:
               name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Jay A. Berzofsky
      affiliation:
            name:National Institutes of Health
            address:
               name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
      name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
      name:Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(192)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.19s.

LINK . SPRINGER . COM {}